Gene Delivery with Organic Electronic Biomaterials.

abstract：:DARPins (designed ankyrin repeat proteins), new kinds of binding proteins, have the potential to overcome the defects of monoclonal antibodies, and hence may become the alternatives to antibodies and generate a novel therapeutic approach. DARPins can be selected to bind any given target proteins with high affinity and...

journal_title：Current pharmaceutical design

authors： Wu X,Shi Y,Ren P,Wang D,Li G

更新日期：2013-01-01 00:00:00

abstract：:Nesfatin-1, derived from the precursor NEFA/nucleobindin2 (NUCB2), was initially identified as a feeding-suppressing neuropeptide, acting at central (mainly, hypothalamic) levels in a leptin-independent manner. However, recent experimental evidence strongly suggests that, rather than being a simple anorectic hypothala...

journal_title：Current pharmaceutical design

authors： García-Galiano D,Tena-Sempere M

更新日期：2013-01-01 00:00:00

abstract：:The clinical presentation of heart disease is different between men and women and this distinction is pivotal for a correct diagnosis and an adequate treatment. However, the definition of symptoms classically associated with heart disease is mainly based on the characteristics of those reported in men. Chest pain or c...

journal_title：Current pharmaceutical design

authors： Collins P,Vitale C,Spoletini I,Barbaro G

更新日期：2011-01-01 00:00:00

abstract：:The development of radioligands to image beta-amyloid (A beta) plaques and neurofibrillary tangles (NFTs) in vivo in the aging human brain is an important and active area of radiopharmaceutical design. When used in combination with positron emission tomography (Pet) or single photon emission computed tomography (spect...

journal_title：Current pharmaceutical design

authors： Mathis CA,Wang Y,Klunk WE

更新日期：2004-01-01 00:00:00

abstract：:Age-associated cognitive decline and dementia are conditions in which there is deterioration in memory, thinking, and behavior, with profound effects on the ability to perform everyday activities and well-being. Even if dementia mainly affects older persons, it is not a normal part of aging. Alzheimer's disease accoun...

journal_title：Current pharmaceutical design

authors： Dominguez LJ,Barbagallo M

更新日期：2016-01-01 00:00:00

abstract：:A small but increasing number of gene expression based biomarkers are becoming available for routine clinical use, principally in oncology and transplantation. These underscore the potential of gene expression arrays and RNA sequencing for biomarker development, but this potential has not yet been fully realized and m...

journal_title：Current pharmaceutical design

authors： Flint SM,McKinney EF,Lyons PA,Smith KG

更新日期：2015-01-01 00:00:00

abstract：:Muscarinic acetylcholine receptors mediate diverse physiological functions. At present, five receptor subtypes (M(1) - M(5)) have been identified. The odd-numbered receptors (M(1), M(3), and M(5)) are preferentially coupled to G(q/11) and activate phospholipase C, which initiates the phosphatidylinositol trisphosphate...

journal_title：Current pharmaceutical design

authors： Ishii M,Kurachi Y

更新日期：2006-01-01 00:00:00

abstract：:Interest in opioid drugs like morphine, as the oldest and most potent pain-killing agents known, has been maintained through the years. One of the most frequent chronic pain sensations people experience is associated with pathological conditions of the musculoskeletal system. Chronic musculoskeletal pain is a major he...

journal_title：Current pharmaceutical design

authors： Spetea M

更新日期：2013-01-01 00:00:00

abstract：:Human arylamine N-acetyltransferases 1 and 2 (NAT1 and NAT2) are polymorphic phase II xenobiotic-metabolising enzymes (XME) that acetylate arylamine compounds. They therefore play an important role in the detoxication and/or metabolic activation of certain therapeutic drugs, occupational chemicals and carcinogens. Alt...

journal_title：Current pharmaceutical design

authors： Rodrigues-Lima F,Dupret JM

更新日期：2004-01-01 00:00:00

abstract：:Among pediatric patients, preterm neonates and newborns are the most vulnerable subpopulation. Rapid developmental changes of physiological factors affecting the pharmacokinetics of drug substances in newborns require extreme care in dose and dose regimen decisions. These decisions could be supported by in silico meth...

journal_title：Current pharmaceutical design

authors： Claassen K,Thelen K,Coboeken K,Gaub T,Lippert J,Allegaert K,Willmann S

更新日期：2015-01-01 00:00:00

abstract：:Transpeptidation reactions result in the formation of new peptide bonds and this can occur between two separate peptides or within the one peptide. These reactions are catalyzed by enzymes and when the N- and C-terminus of the one peptide are joined it results in the formation of cyclic proteins. Cyclization via head-...

journal_title：Current pharmaceutical design

authors： Conlan BF,Anderson MA

更新日期：2011-12-01 00:00:00

abstract：BACKGROUND:Inhibition of hepatic fibrosis is an attainable objective in managing the chronic liver disease. The present study aimed to investigate possible defensive effects of metformin on the activities of antioxidant enzymes, hydroxyproline content, and biochemical factors in bile duct ligation (BDL)-induced cholest...

journal_title：Current pharmaceutical design

authors： Mansourian M,Sadeghi H,Doustimotlagh AH

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:A high dietary intake of polyphenols has been associated with a reduced cardiovascular mortality, due to their antioxidant properties. However, growing evidence suggests that counteracting oxidative stress in cardiovascular disease might also reduce sympathetic nervous system overactivity. METHODS:This arti...

journal_title：Current pharmaceutical design

authors： Bruno RM,Ghiadoni L

更新日期：2018-01-01 00:00:00

abstract：:The pharmacophore concept is central to the rational drug design and discovery process. Traditionally, a pharmacophore is defined as a specific three-dimensional (3D) arrangement of chemical functional groups found in active molecules, which are characteristic of a certain pharmacological class of compounds. Herein, b...

journal_title：Current pharmaceutical design

authors： Tropsha A,Zheng W

更新日期：2001-05-01 00:00:00

abstract：:The phenomenon of blood serum atherogenicity was described as the ability of human serum to induce lipid accumulation in cultured cells. The results of recent two-year prospective study in asymptomatic men provided the evidence for association between the changes in serum atherogenicity and dynamics of carotid intima-...

journal_title：Current pharmaceutical design

authors： Sobenin IA,Myasoedova VA,Anisimova EV,Pavlova XN,Möhlenkamp S,Schmermund A,Seibel R,Berenbein S,Lehmann N,Moebus S,Jöckel K,Orekhov AN,Erbel R

更新日期：2014-01-01 00:00:00

abstract：:BMS-378806 is a prototype of a new class of small molecule HIV-1 inhibitors that blocks viral attachment to cells. This compound exhibits potent inhibitory activity against a panel of HIV-1 laboratory and clinical isolates (M- and T-tropic), selective for HIV-1 and inactive against HIV-2, SIV and a panel of other viru...

journal_title：Current pharmaceutical design

authors： Wang HG,Williams RE,Lin PF

更新日期：2004-01-01 00:00:00

abstract：:Phase-change contrast agents (PCCAs) for ultrasound-based applications have resulted in novel ways of approaching diagnostic and therapeutic techniques beyond what is possible with microbubble contrast agents and liquid emulsions. When subjected to sufficient pressures delivered by an ultrasound transducer, stabilized...

journal_title：Current pharmaceutical design

authors： Sheeran PS,Dayton PA

更新日期：2012-01-01 00:00:00

abstract：:Cerebral ischemia is one of the major causes of disability worldwide. In cerebral ischemic stroke, occlusion of a major cerebral artery by an embolus or local thrombosis can result in transient or permanent reduction of cerebral blood flow to a portion of the brain, resulting in deprivation of glucose and oxygen. Sinc...

journal_title：Current pharmaceutical design

authors： Shah K,Abbruscato T

更新日期：2014-01-01 00:00:00

abstract：:Transient left ventricular dysfunction in patients under emotional stress, also known as Takotsubo cardiomyopathy, has been recognized as a distinct clinical entity. Recent studies have supported the concept notion that the cardiovascular system is regulated by cortical modulation. A network consisting of the insular ...

journal_title：Current pharmaceutical design

authors： Nagai M,Dote K,Kato M,Sasaki S,Oda N,Kagawa E,Nakano Y,Yamane A,Higashihara T,Miyauchi S,Tsuchiya A,Harada W,Kario K

更新日期：2017-01-01 00:00:00

abstract：:Abnormal regulation of the ubiquitin-proteasome system (UPS) has been known to be involved in the pathogenesis of a variety of human diseases. A number of studies have focused on the identification of small modifiers for the UPS. Even though the proteasome inhibitor Bortezomib (Velcade®) has been approved for the ther...

journal_title：Current pharmaceutical design

authors： Lim KH,Baek KH

更新日期：2013-01-01 00:00:00

abstract：:Type 2 diabetes is associated with substantially increased cardiovascular mortality. The need to reduce the progression of atherosclerosis alongside lowering blood glucose levels is now well established. Ideally, pharmaceutical treatment should address both of these needs. This review summarises current evidence of th...

journal_title：Current pharmaceutical design

authors： Papanas N,Maltezos E

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) is a global epidemic involving 20-40% of the general population. NAFLD is rapidly becoming the leading cause of hepatocellular carcinoma (HCC) worldwide. Knowledge about NAFLD-HCC peculiar features is needed to understand this emerging disease better. OBJECTIVE:To r...

journal_title：Current pharmaceutical design

authors： Tovoli F,Ferri S,Piscaglia F

更新日期：2020-01-01 00:00:00

abstract：:Polyunsaturated fatty acids (PUFA) are a family of lipids including some subgroups identified by the position of the last double bond in their structure. PUFA n-3 include alpha linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), while PUFA n-6 include linoleic acid (LA) and arachidonic a...

journal_title：Current pharmaceutical design

authors： Zuliani G,Galvani M,Leitersdorf E,Volpato S,Cavalieri M,Fellin R

更新日期：2009-01-01 00:00:00

abstract：:Toll-like receptors (TLRs) have emerged as critical players in immunity. They are capable of sensing organisms ranging from protozoa to bacteria, fungi or viruses upon detection of the pathogen as well as recognizing endogenous ligands, and triggering transduction pathways. Following activation of the innate immune sy...

journal_title：Current pharmaceutical design

authors： de la Barrera S,Alemán M,Sasiain Mdel C

更新日期：2006-01-01 00:00:00

abstract：:Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common cause of chronic liver disease worldwide. This is primarily driven by the global epidemic of obesity and diabetes as well as the aging of the general population. Most of the epidemiology data of NAFLD for North America are published from stud...

journal_title：Current pharmaceutical design

authors： Arshad T,Golabi P,Henry L,Younossi ZM

更新日期：2020-01-01 00:00:00

abstract：:Gonadotropin Releasing Hormone (GnRH) is at the centre of the scientific debate for the treatment of hypogonadotropic hypogonadism. Sexual maturation and reproductive function depend on the pulsatile secretion of GnRH are mainly congenital and may or may not be associated with other genetic anomalies or syndromes. Cli...

journal_title：Current pharmaceutical design

authors： Bettocchi C,Rinaldi M,Sebastiani F

更新日期：2020-11-24 00:00:00

abstract：:Low density lipoproteins (LDL) and high density lipoproteins (HDL) are independent risk factors for coronary heart disease (CHD); decreasing LDL-cholesterol (LDL-C) levels with statin therapy represents the primary goal in the management of cardiovascular disease. However, despite the efficacy of statins in reducing c...

journal_title：Current pharmaceutical design

authors： Pirillo A,Norata GD,Catapano AL

更新日期：2013-01-01 00:00:00

abstract：:Over the last decade, much was learned about the biology of several types of stem and progenitor cells. It has become apparent that various cell sources may have the capacity to promote cardiomyogenesis and new blood vessel formation through different mechanisms, forming the rationale for cell-based therapy in patient...

journal_title：Current pharmaceutical design

authors： Rodrigo SF,Ramshorst Jv,Beeres SL,Bax JJ,Schalij MJ,Atsma DE

更新日期：2011-10-01 00:00:00

abstract：:Aspirin has been one of the most widely used medications since its first synthesis more than 100 years ago. In addition to short-term use for pain and fever relief, regular use of aspirin has been shown to reduce the risk of cardiovascular diseases and strokes. The issue of regular aspirin use in cancer prevention is ...

journal_title：Current pharmaceutical design

authors： Huang WK,Tu HT,See LC

更新日期：2015-01-01 00:00:00

abstract：:Regulation of cellular redox balances is important for the homeostasis of human health. Thus, many important human diseases, such as inflammation, diabetes, glaucoma, cancers, ischemia and neurodegenerative diseases, have been investigated in the field of reactive oxygen species (ROS) and oxidative stress. To overcome...

journal_title：Current pharmaceutical design

authors： Noda M,Fujita K,Lee CH,Yoshioka T

更新日期：2011-01-01 00:00:00